Gentle swirlingrather than shakinghelps the powder dissolve evenly and maintains the integrity of the peptide solution
ActiGraft System, HCPCS Code G0465 (APC 5054) Effective April 2021, HCPCS code G0465 (Autologous platelet rich plasma (PRP) or other blood-derived product for diabetic chronic wounds/ulcers, using an FDA-cleared device for this indication, (includes as applicable administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment) describes autologous blood derived products for chronic non-healing wounds
This ratio is clear and helps reduce mistakes during daily use
Every compound is independently third-party tested, with a lot-matched Certificate of Analysis (COA) and a GHS-format Safety Data Sheet (SDS) available for download
NO completed peer-reviewed trials for individual peptides Research Limitations & Regulatory Status Critical Gaps in Current Evidence Despite extensive preclinical research on individual peptides, the BPC-157 + TB-500 combination faces substantial translational barriers that severely limit its research utility and prevent any clinical application
